PeptideStack
5.2kquestions
20kanswers
220users

What does a payer want to see before approving tirzepatide?

Asked 2 Oct 2025Modified 7 months agoViewed 12k times
11

I have been through one internal appeal already and would like to do the next one properly.

I want a method I can write down and repeat, not a rule of thumb.

I would rather over-engineer this than discover a problem later, within reason.

So: what is the actual procedure, and which steps matter as opposed to being ritual?

prior-authorization
prior-authorization

Prior authorisation mechanics: medical-necessity criteria, documenting a lifestyle-intervention requirement, step therapy, and the…

19 questions
insurance
insurance

Coverage: formulary tiers, exclusion versus non-coverage, the difference a diabetes indication makes, employer carve-outs, and what an appeal…

35 questions
t2dm
t2dm

Type 2 diabetes: glycaemic endpoints, the SURPASS and SUSTAIN programmes, dose ranges licensed for diabetes versus obesity, and interaction with…

22 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
shareeditfollowflag
DK
askedDr_Sara_Kuusela28k372 Oct 2025
Is the product approved or compounded? That changes everything downstream. – plate_count_9k 6 months ago
add a comment

3 Answers

Accepted answer first, then by votes
62

Accepted answer

Answer first: a prior authorisation is a documentation exercise against published criteria, and it is won or lost on whether the record contains the required elements.

The denial letter states a specific reason. The appeal should address that reason first and explicitly, with the missing evidence attached, rather than restating the original case.

Each criterion must be evidenced in the clinical record, dated, before the request. A criterion asserted in a covering letter but absent from the notes is the commonest reason for a denial.

Medical policies stating prior-authorisation criteria are published by plans and are obtainable before submission.

The caveat is that this is administrative navigation and nothing here is clinical or legal advice.

Get the criteria first. A request written blind is a request written badly.

shareimprove this answerflag
PH
answered · acceptedpetra_hovland35k3827 Nov 2025
Adding a vote because this deserves more of them. – meniscus_film 6 months ago
Thank you — this is the answer I was looking for. – RP_C18 5 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
53

Answering this needs the plan, since criteria vary and a general answer is not actionable.

Obtain the medical policy for the specific drug and plan first. It lists the required diagnosis codes, thresholds, documented durations and any prerequisite therapy, and it is the checklist the reviewer works from.

Submit the supporting documents with the request rather than waiting to be asked. Requests denied for insufficient information are denials that a complete submission would have avoided.

Processes differ by jurisdiction and by plan, so any general description will be wrong somewhere.

Attach everything on the first submission. Incomplete is the commonest denial.

edited 31 Dec 2025 by Dr_Elias_Weiss — added the placebo-arm figures

shareimprove this answerflag
DW
answeredDr_Elias_Weiss25k278 Dec 2025
26

The short version: get the criteria, evidence each one in the record, submit with the documentation attached, and appeal a denial with the reason addressed.

Where prerequisite therapy is required, the record needs the agent, the dates, the dose and the reason it was stopped. "Tried and failed" without those four elements is not documentation.

Track the deadlines. Appeal windows are finite, and a well-founded appeal filed late is worth nothing at all.

Peer-to-peer review is a standard step in utilisation-management processes and resolves a meaningful share of disputes.

A prescriber has to submit the request; this is a description of what makes one succeed, not a substitute for one.

The denial reason is the appeal specification. Address it directly.

shareimprove this answerflag
DT
answeredday_seven_trough6.7k1416 Nov 2025
5Same experience here, different supplier. – u100_marks 6 days ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.